Capstone Therapeutics to Hold Quarterly Update Conference Call
August 23, 2011 08:00 ET
|
Capstone Therapeutics
TEMPE, Ariz., Aug. 23, 2011 (GLOBE NEWSWIRE) -- Capstone Therapeutics (OTCQB:CAPS); (the "Company"), today will hold a conference call and webcast to provide a quarterly Company update.
Conference...
Capstone Therapeutics to Host Quarterly Update Conference Call
August 19, 2011 13:16 ET
|
Capstone Therapeutics
TEMPE, Ariz., Aug. 19, 2011 (GLOBE NEWSWIRE) -- Capstone Therapeutics (OTCQB:CAPS) (the "Company") will host a conference call and webcast on Tuesday, August 23, 2011 at 1:00 pm EDT / 10:00 am PDT....
Capstone Therapeutics Announces Pre-Clinical Results With AZX100 in Radiation and Bleomycin Models of Pulmonary Fibrosis; Pulmonary Anti-Fibrotic Effect Demonstrated
July 06, 2011 08:00 ET
|
Capstone Therapeutics
TEMPE, Ariz., July 6, 2011 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS) (the "Company") today announced results from a pre-clinical study of AZX100 in a rodent model of radiation-induced...
Capstone Therapeutics Announces Adjournment of Its Annual Meeting of Stockholders and Intention to Reconvene the Meeting on June 28, 2011
June 08, 2011 12:30 ET
|
Capstone Therapeutics
TEMPE, Ariz., June 8, 2011 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS) (the "Company") announced that at its Annual Meeting held on Monday June 6, 2011, there were insufficient shares...
Capstone Therapeutics Signs Alliance With BiolineRx to Develop Chrysalin (TP508) in Acute Myocardial Infarction
May 31, 2011 14:00 ET
|
Capstone Therapeutics
TEMPE, Ariz., May 31, 2011 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS) (the "Company") today announced a material transfer agreement with BiolineRx (Jerusalem) to develop Chrysalin (TP508)...
Capstone Therapeutics Reminds Stockholders of Annual Meeting on June 6, 2011 and Encourages All Stockholders to Vote
May 26, 2011 17:00 ET
|
Capstone Therapeutics
TEMPE, Ariz., May 26, 2011 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS) (the "Company") reminds stockholders that its Annual Meeting is scheduled for Monday June 6, 2011 and encourages all...
Capstone Therapeutics Confirms Early Signal of AZX100 Effect Based on Final Results of Phase 2a Pilot Clinical Trial in Surgical (Trocar Site) Scarring
April 27, 2011 16:45 ET
|
Capstone Therapeutics
TEMPE, Ariz., April 27, 2011 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS) (the "Company") today announced that the final results from its AZX100 Phase 2a pilot clinical trial in surgical...
Capstone Therapeutics Announces Update to Timing of Release of Final Results From AZX100 Phase 2a Pilot Clinical Trial in Surgical (Trocar Site) Scarring
April 04, 2011 16:05 ET
|
Capstone Therapeutics
TEMPE, Ariz., April 4, 2011 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS) (the "Company") today announced an update to the reporting schedule for twelve-month results from its AZX100 Phase...
Capstone Therapeutics to Present at Biotech Showcase 2011
January 06, 2011 16:52 ET
|
Capstone Therapeutics
TEMPE, Ariz., Jan. 6, 2011 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS) is scheduled to make a presentation at the Biotech Showcase 2011, Parc 55 Wyndham San Francisco – Union Square,...
Capstone Therapeutics Announces Results of AZX100 Phase 2a Pilot Clinical Trials in Keloid and Surgical Scarring
December 13, 2010 21:18 ET
|
Capstone Therapeutics
TEMPE, Ariz., Dec. 13, 2010 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS) (the "Company") announced today twelve-month results from its two AZX100 Phase 2a pilot clinical trials in keloid...